Upper Panel: Plasma estradiol (A) and progesterone (B) were significantly increased in the three months of estradiol/progesterone addback compared with the last month of leuprolide and the month of single-blind placebo. There were no significant differences in plasma levels between the first month of estradiol/progesterone addback compared with the second and third months of estradiol/progesterone addback.
Lower Panel: The pattern of between month differences in symptom severity reflects the presence of significantly increased Premenstrual Tension-self (C) and –rater (D) scores during the first month of estradiol/progesterone (E/P in figure) addback (Month 5) compared with all other months (i.e., last month of leuprolide alone, placebo, and the second and third months of estradiol/progesterone addback). In contrast, there were no significant differences in symptom severity scores in either Premenstrual Tension-self or –rater scores between the last month of leuprolide alone (Month 3) and scores during placebo, second and third month of estradiol/progesterone addback. Finally, Premenstrual Tension scores in the second and third months of estradiol/progesterone addback also were not significantly different.